Stratos Wealth Partners LTD. Sells 314 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Stratos Wealth Partners LTD. lessened its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 17.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,523 shares of the medical research company’s stock after selling 314 shares during the period. Stratos Wealth Partners LTD.’s holdings in Charles River Laboratories International were worth $281,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in CRL. Versant Capital Management Inc grew its stake in shares of Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after acquiring an additional 150 shares during the period. Wolff Wiese Magana LLC purchased a new stake in Charles River Laboratories International in the third quarter worth approximately $32,000. Pinnacle Bancorp Inc. raised its stake in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after buying an additional 65 shares during the last quarter. Assetmark Inc. lifted its holdings in shares of Charles River Laboratories International by 1,153.3% during the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after buying an additional 173 shares during the period. Finally, ORG Wealth Partners LLC purchased a new position in shares of Charles River Laboratories International in the 4th quarter worth $56,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

CRL has been the topic of several research reports. TD Cowen raised their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday, November 11th. Morgan Stanley cut their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 5th. William Blair cut shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. UBS Group restated a “neutral” rating and issued a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Finally, CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a report on Monday, November 18th. Three research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $200.79.

Charles River Laboratories International Trading Down 0.5 %

Shares of NYSE:CRL opened at $153.20 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The firm has a market capitalization of $7.83 billion, a P/E ratio of 19.17, a P/E/G ratio of 6.47 and a beta of 1.37. The business’s 50-day moving average is $177.23 and its 200 day moving average is $191.71. Charles River Laboratories International, Inc. has a 1 year low of $150.79 and a 1 year high of $275.00.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).